|
|
Post by figglebird on Sept 17, 2018 12:12:03 GMT -5
Obviously, this does not in any way directly implicate TS but does beg the question I have held since my initial investment - as new drug molecules address new and old needs/problems, what are the chances TS plays a role delivering such molecules into a patients system... I gotta believe, knowing the little I do about Samumed's impressive clinical ambitions that their particular aerosol/pulmonary delivery(which is not a focus of their work as far as I understand) might be improved somewhat by a different route or formulation... The timing at the very least is very interesting and should lead to more questions regarding the breadth or width of TS's moat. These last questions might be better answered the more we understood who and what was behind experimental candidates for the TS platform. It would not take much to become a legitimate hybrid pharma of the future - funding - molecule - delivery... Not saying this is a trio but could be in worse company etc. ir.unither.com/news-releases/news-release-details/samumed-and-united-therapeutics-announce-north-american-license |
|
|
|
Post by figglebird on Sept 17, 2018 12:12:35 GMT -5
|
|
|
|
Post by tomtabb on Sept 17, 2018 13:52:15 GMT -5
Deal sounds similar to MNKD's -- "Under the terms of the agreement, United Therapeutics' subsidiary, Lung Biotechnology PBC, will conduct and fund all further development, regulatory and commercialization activities in the U.S. and Canada." They have been active raising money -- www.samumed.com/medium/image/samumed-closes-on-438-million-in-equity-financing_371/view.aspx"August 6, 2018 –Samumed, LLC,announced today that it has closed its A-6 Round of equity issuance with $438 million, bringing its total equity raisedto date to more than $650 million." I'm guessing that made UTHR sit up and take notice. |
|
|
|
Post by figglebird on Sept 17, 2018 14:02:48 GMT -5
I'm not unconvinced they do not already own a piece - in terms of funding - obviously public companies fund private ones constantly so no reason to believe they have not
|
|
|
|
Post by goyocafe on Sept 17, 2018 14:34:02 GMT -5
|
|
|
|
Post by jlaw277 on Sept 17, 2018 14:42:47 GMT -5
Deal sounds similar to MNKD's -- "Under the terms of the agreement, United Therapeutics' subsidiary, Lung Biotechnology PBC, will conduct and fund all further development, regulatory and commercialization activities in the U.S. and Canada." They have been active raising money -- www.samumed.com/medium/image/samumed-closes-on-438-million-in-equity-financing_371/view.aspx"August 6, 2018 –Samumed, LLC,announced today that it has closed its A-6 Round of equity issuance with $438 million, bringing its total equity raisedto date to more than $650 million." I'm guessing that made UTHR sit up and take notice. The $12 billion pre-money valuation made me take notice. Makes me realize how incredibly undervalued MNKD is. |
|
|
|
Post by buyitonsale on Sept 17, 2018 17:47:03 GMT -5
Why are their development milestones much bigger than ours?
Because of a new molecule or a larger market?
|
|
|
|
Post by mnholdem on Sept 17, 2018 19:17:36 GMT -5
Treatments average $100,000 per year plus the clinical trials have only started (Phase 1) for what could become a First-in-Class drug for idiopathic pulmonary fibrosis (IPF). MannKind has only the Phase 3 trial remaining for TreT and it will be relatively inexpensive.
|
|
|
|
Post by falconquest on Sept 17, 2018 19:38:22 GMT -5
I don't mean to be a smartass but doesn't this thread belong on the "Other Biopharma Stocks" board?
|
|
|
|
Post by brotherm1 on Sept 17, 2018 19:52:16 GMT -5
No, it’s relevant here
|
|
|
|
Post by mnholdem on Sept 17, 2018 20:08:32 GMT -5
I don't mean to be a smartass but doesn't this thread belong on the "Other Biopharma Stocks" board? It probably would have been moved but for the fact that United Therapeutics just signed an Agreement with MannKind which has provisions for additional API. MannKind may have “locked in” the price UTC must pay upfront for development of additional Technosphere API, but MannKind also limited what therapeutic areas these would apply to and what is not. I’m of the opinion that discussion about how much United Therapeutics might being willing pay for a unique API is appropriate for this area of the board. |
|
|
|
Post by buyitonsale on Sept 24, 2018 21:06:04 GMT -5
In today's UT science day Samumed was presenting their IPF and other programs. I was very impressed by their drug design approach.
They said the UT will own rights to their IPF molecule in North America as a drug / device combination.
I wonder if Mankind may have been tasked by UT to investigate if Technosphere can deliver that molecule... not sure if it makes sense
given that Samumed will get royalties, but I agree with original post that there may be a future collaboration.
|
|
|
|
Post by figglebird on Sept 25, 2018 4:17:18 GMT -5
Bf I posted this topic, I recall emailing Mike C a question regarding his thoughts on collaborating w lung biotech which is uthrs subsidiary company that developed the inhallable powder for samusets trials. Though he is responsive in general - I was not expecting him to respond. I was just excited. And I just couldn’t hide it. I felt like I was going to lose control and I thought I liked it. Anyhow my hope would be that their is some literal meaning here to the other non pah api component in our deal w uthr -some cross over with samuset a 12 billion dollar biotech - this is a pathway that could yield a Boston scientific kind of valuation for mnkd if successful - the conglomerate team approach etc.
|
|
|
|
Post by mango on Sept 25, 2018 4:56:16 GMT -5
Guessing UT intends to utilize Technosphere for developing a dry powder formulation of Samumed’s small molecule, SM04646, and deliver it via a MannKind inhaler. SM04646, a Wnt pathway inhibitor, is currently undergoing a phase 1 clinical trial. Under the terms of the agreement, United Therapeutics' subsidiary, Lung Biotechnology PBC, will conduct and fund all further development, regulatory and commercialization activities in the U.S. and Canada. Samumed retains development and commercialization rights for all markets outside of North America. "I've been impressed with Samumed's exhaustive work on the pleiotropic Wnt pathway from the time I met Dr. Kibar at this year's Cura Foundation conference on regenerative medicine, held at the Vatican," said Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of Lung Biotechnology PBC. " Our months of due diligence have energized our belief in SM04646's fibrosis-modulating properties, and hence unique potential for addressing IPF." ir.unither.com/news-releases/news-release-details/samumed-and-united-therapeutics-announce-north-american-license• SM04646 Inhibited Wnt Pathway Gene Expression Stimulated in Response to Transforming Growth Factor-beta and was Effective in a Chronic Model of Bleomycin-induced Pulmonary Fibrosiswww.samumed.com/medium/image/samumed-announces-presentation-at-the-2018-american-thoracic-society-ats-international-conference_315/view.aspx • Discovery of a Small Molecule Inhibitor of the Wnt pathway (SM04646) Delivered as an Inhaled Aerosol for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)1. Abstracts www.samumed.com/medium/image/pulmonary-fibrosis-foundation-summit-pff-11092017_218/view.aspxwww.samumed.com/medium/image/american-thoracic-society-ats-washington-d-c-05192017_89/view.aspx2. Poster www.samumed.com/medium/image/pulmonary-fibrosis-foundation-summit-pff-11092017_219/view.aspx• SM04646 inhibited Wnt pathway gene expression stimulated in response to Transforming Growth Factor-β and was effective in a chronic model of Bleomycin-induced pulmonary fibrosis1. Abstract www.samumed.com/medium/image/american-thoracic-society-ats-05182018_327/view.aspx2. Poster www.samumed.com/medium/image/american-thoracic-society-ats-05182018_328/view.aspx• A Phase 1, Open-Label Study, to Evaluate the Safety and Tolerability of multiple inhalation of SM04646 Inhalation Solution in Subjects with Mild to Moderate Idiopathic Pulmonary Fibrosis (IPF)www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=372519&isReview=true• A Phase 1, Open-Label Study, to Evaluate the Safety and Tolerability of a Single Inhalation of SM04646 Solution in Healthy Subjectswww.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=369623&isReview=true• SAMUMED RECEIVES ORPHAN DRUG DESIGNATION FROM FDA FOR SM04646 AS A TREATMENT FOR IDIOPATHIC PULMONARY FIBROSIS (IPF)www.samumed.com/medium/image/samumed-receives-orphan-drug-designation-from-fda-for-sm04646-as-a-treatment-for-idiopathic-pulmonary-fibrosis-ipf_141/view.aspx• SAMUMED SUCCESSFULLY COMPLETED PHASE I STUDY FOR POTENTIAL TREATMENT OF IDIOPATHIC PULMONARY FIBROSISwww.samumed.com/medium/image/samumed-successfully-completed-phase-1-study-for-the-potential-treatment-of-idiopathic-pulmonary-fibrosis_134/view.aspxCurious if Samumed has any plans to develop biophotonic medical technologies, saw the CEO has a PhD specializing in biophotonics and photoelectronics. |
|
|
|
Post by kc on Sept 25, 2018 16:24:49 GMT -5
Different disease being treated than PAH.....
Samumed LLC has entered an exclusive license agreement with United Therapeutics Corporation (Nasdaq: UTHR) for North American rights to Samumed's SM04646, being developed for the treatment of idiopathic pulmonary fibrosis (IPF). Deal terms include $10 million up-front, plus up to $340 million in developmental milestones and up to low double-digit royalties.
|
|
